Current Setup & Catalysts
Current Setup & Catalysts
Figures converted from INR to USD at ₹94.52 per USD (May 9, 2026 rate). Ratios, margins, multiples, and day-count metrics are unchanged.
The stock is at $18.65 two days after releasing FY2026 results that confirmed record revenue but the first year-on-year PAT decline in eight quarters, and the market is now watching whether the 139-day cash conversion cycle — the worst in twelve years — normalises in Q1 FY2027 (results expected July 29, 2026) as the RMIL copper acquisition begins contributing its first consolidated revenue. Price has recovered 39% from the April 2, 2026 low of $13.40, aided by the RMIL announcement and bargain buying after an RSI that hit 17.0 in January 2026, but the rally has run on average volume with no institutional block print to confirm re-entry. Consensus is unanimously bullish (9/9 Buy, average target $22.08), yet the fundamental tension between record-profit P&L and negative free cash flow remains unresolved. The next 90 days carry two hard catalysts that will either confirm or break the current 34× trailing P/E: Phagi plant commissioning in June 2026 and the Q1 FY2027 earnings print on July 29.
Current Price (USD)
Hard-Dated Catalysts (6 Months)
High-Impact Catalysts
Days to Q1 FY27 Results (Jul 29)
Q4 FY2026 (reported May 7, 2026): record quarterly revenue $124M (+13.1% YoY), but EBITDA fell 5.1% YoY and net profit fell 3.4% YoY to $9.7M — the first YoY PAT decline in at least eight consecutive quarters. Full-year cash conversion cycle reached 139 days (FY25: 92 days), a 12-year worst. FCF for FY2026 was -$4.9M despite record PAT of $40M. The stock fell 2.04% on May 8 on 3.5× average daily volume (74,517 shares vs 21,164 average).
What Changed in the Last 3–6 Months
The narrative arc from September 2024 through May 2026 has three distinct phases. From September 2024 to April 2026, the market de-rated GRAVITA from $28.57 (ATH) to $13.40 (52-week low), repricing ROCE compression from 32% to 17%, a $52.7M founder sell-down, and two consecutive negative-FCF years. From April to May 2026, RMIL copper and technical bargain buying drove a 39% recovery on average volume — optionality re-priced, quality-of-earnings debate deferred. As of today (May 9, 2026), the market has not resolved whether FCF normalization will confirm the bull thesis or whether structural working capital deterioration will force estimate cuts. The first hard evidence arrives July 29.
Quarterly Earnings Trend — Last Eight Quarters
Q4 FY2026 delivered the highest quarterly revenue on record ($124M) but net profit of $9.7M was the lowest in three quarters and below Q4 FY2025 ($10.1M) — the first YoY PAT decline visible in this series. The trajectory had been consistently improving from Q1 FY25 ($7.2M) through Q3 FY26 ($10.3M); Q4's reversal is the data point now anchoring the "structural vs transitional" debate. The Q1 FY27 consensus EPS estimate implies the market expects flat-to-slightly-declining sequential earnings — a conservative assumption that could easily be beaten if CCC normalises.
What the Market Is Watching Now
Ranked Catalyst Timeline
Impact Matrix
Next 90 Days
What Would Change the View
Three signals would most change the debate. Q1 FY2027 CCC (July 29): below 100 days confirms the expansion-artefact thesis; above 130 days triggers sell-side estimate cuts and makes 34× indefensible without a credible ROCE recovery path. RMIL copper EBITDA per tonne — once disclosed — resolves whether the acquisition follows the lead-tolling template ($265+) or the aluminium-dilution template (sub-$159 or deliberate non-disclosure). Any promoter open-market purchase below $21.07 would be the first insider conviction signal in 24 months; further selling at current prices confirms the founder's exit was not at a trough.
All monetary figures are converted to USD at ₹94.52 per USD. Financial data in USD millions where noted. Analyst estimates from public filings; no broker consensus database available. Key dates: Q4 FY2026 reported May 7, 2026; Q1 FY2027 results estimated July 29, 2026.